ATE405564T1 - 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten - Google Patents

1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten

Info

Publication number
ATE405564T1
ATE405564T1 AT03730079T AT03730079T ATE405564T1 AT E405564 T1 ATE405564 T1 AT E405564T1 AT 03730079 T AT03730079 T AT 03730079T AT 03730079 T AT03730079 T AT 03730079T AT E405564 T1 ATE405564 T1 AT E405564T1
Authority
AT
Austria
Prior art keywords
treatment
protein kinase
imidazoä4
cuchinolin
derivatives
Prior art date
Application number
AT03730079T
Other languages
English (en)
Inventor
Carlos Garcia-Echeverria
Hans-Georg Capraro
Pascal Furet
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE405564T1 publication Critical patent/ATE405564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03730079T 2002-05-21 2003-05-20 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten ATE405564T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0211649.9A GB0211649D0 (en) 2002-05-21 2002-05-21 Organic compounds

Publications (1)

Publication Number Publication Date
ATE405564T1 true ATE405564T1 (de) 2008-09-15

Family

ID=9937093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03730079T ATE405564T1 (de) 2002-05-21 2003-05-20 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten

Country Status (15)

Country Link
US (1) US7998972B2 (de)
EP (1) EP1509521B8 (de)
JP (1) JP4707389B2 (de)
CN (1) CN100475207C (de)
AT (1) ATE405564T1 (de)
AU (1) AU2003240680A1 (de)
BR (1) BR0311221A (de)
CA (1) CA2485012A1 (de)
DE (1) DE60323090D1 (de)
DK (1) DK1509521T3 (de)
ES (1) ES2312783T3 (de)
GB (1) GB0211649D0 (de)
PT (1) PT1509521E (de)
SI (1) SI1509521T1 (de)
WO (1) WO2003097641A2 (de)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
CA2475595C (en) 2002-02-22 2012-07-10 3M Innovative Properties Company Method of reducing and preventing uvb-induced immunosuppression
WO2003103584A2 (en) 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
DE60312701T8 (de) * 2002-07-26 2008-08-21 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Darstellung von 1h-imidazo[4,5-c]chinolin-4-aminen über neue 1h-imidazo[4,5-c] chinolin-4-cyano- und 1h-imidazo[4,5-c]chinolin-4-carboxamid intermediate
CA2510375A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2004110991A2 (en) 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
JP2007501252A (ja) 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調整剤を含有する製剤
AR045261A1 (es) * 2003-08-12 2005-10-19 3M Innovative Properties Co Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores
US7799800B2 (en) * 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
JP2007503268A (ja) 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
ES2406730T3 (es) 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
NZ546274A (en) 2003-10-03 2009-12-24 3M Innovative Properties Co Pyrazolopyridines and analags thereof
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
US7897767B2 (en) * 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
MXPA06005910A (es) 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
EP1686992A4 (de) * 2003-11-25 2009-11-04 3M Innovative Properties Co Hydroxylamin- und oxim-substituierte imidazochinoline, imidazopyridine und imidazonaphthyridine
EP1689361A4 (de) 2003-12-02 2009-06-17 3M Innovative Properties Co Therapeutische kombinationen und verfahren mit irm-verbindungen
JP2007513170A (ja) * 2003-12-04 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー スルホン置換イミダゾ環エーテル
EP1701955A1 (de) 2003-12-29 2006-09-20 3M Innovative Properties Company Arylalkenyl- und arylalkinylsubstituierte imidazochinoline
US7888349B2 (en) * 2003-12-29 2011-02-15 3M Innovative Properties Company Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
CA2559863A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
EP1765348B1 (de) * 2004-06-18 2016-08-03 3M Innovative Properties Company Substituierte imidazochinoline, imidazopyridine sowie imidazonaphthyridine
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8143270B2 (en) 2004-09-02 2012-03-27 3M Innovative Properties Company 2-amino 1H-in-imidazo ring systems and methods
US7579359B2 (en) * 2004-09-02 2009-08-25 3M Innovative Properties Company 1-alkoxy 1H-imidazo ring systems and methods
WO2006070379A1 (en) * 2004-12-27 2006-07-06 Usv Limited A process for preparation of 4-amino-1-isobutyl-1h-imidazo[4,5-c]-quinoline (imiquimod)
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
BRPI0519302A2 (pt) * 2004-12-30 2009-01-06 Takeda Pharmaceutical etanossulfonato de sais de 1-(2-metilpropil)-1h-imidazo[4,5-c][1,5]naftiridin-4-amin o e metanossulfonato de 1-(2-metilpropil)-1h-imidazo[4,5-c][1,5]naftiridin-4-amin a, composiÇÕes contendo os mesmos, processos de preparaÇço e uso
ES2392648T3 (es) 2004-12-30 2012-12-12 3M Innovative Properties Company Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
JP2008526757A (ja) * 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤製剤および方法
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
PT1830876E (pt) 2004-12-30 2015-07-13 Meda Ab Utilização de imiquimod para o tratamento de metástases cutâneas derivadas de um tumor cancerígeno da mama
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
EP1846419B1 (de) 2005-02-09 2014-04-16 3M Innovative Properties Company Alkoxysubstituierte Thiazolochinoline und Thiazolonaphthyridine
WO2007120121A2 (en) 2005-02-09 2007-10-25 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
JP2008543725A (ja) 2005-02-23 2008-12-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン
JP2008531568A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキルで置換されたイミダゾナフチリジン
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
AU2006216686A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
JP2008538550A (ja) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ，インコーポレイテッド ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ITMI20051292A1 (it) * 2005-07-08 2007-01-09 Dipharma Spa Procedimento per la purificazione di imiquimod
CA2621831A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
JP5247458B2 (ja) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
KR101395615B1 (ko) * 2005-11-30 2014-05-16 미쓰비시 가가꾸 가부시키가이샤 유기 화합물, 전하 수송 재료, 전하 수송 재료용 조성물 및유기 전계 발광 소자
EP1988896A4 (de) 2006-02-22 2011-07-27 3M Innovative Properties Co Konjugate zur modifizierung von immunreaktionen
CA2645137A1 (en) 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
TW200813021A (en) * 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
CN101115224B (zh) * 2006-07-28 2010-06-16 华为技术有限公司 用于ims网络的短信分叉方法及系统
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
CN102336752A (zh) 2006-11-20 2012-02-01 诺瓦提斯公司 2-甲基-2-[4-(3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢-咪唑并[4,5-c]喹啉-1-基)-苯基]-丙腈的盐和晶型
KR101532256B1 (ko) 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US9370508B2 (en) * 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
JP5519627B2 (ja) * 2008-03-26 2014-06-11 ノバルティス アーゲー Ｖｅｇｆ促進性血管新生過程の強力なモジュレーターとしての５イミダゾキノリン誘導体およびピリミジン誘導体
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EP2371826A4 (de) 2008-12-29 2012-06-27 Takeda Pharmaceutical Neue verbindung mit kondensierten ringen und ihre verwendung
CN102574845B (zh) * 2009-06-04 2015-09-02 诺华股份有限公司 1H-咪唑并[4,5-c]喹啉酮衍生物
WO2011001212A1 (en) * 2009-06-30 2011-01-06 Piramal Life Sciences Limited Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2485591B1 (de) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazindioxinverbindungen als bace-hemmer, zusammensetzungen und ihre verwendung
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
EP2485920B1 (de) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Heterozyklische pentafluorsulfur-imin-verbindungen als bace-1-hemmer sowie zusammensetzungen damit und ihre verwendung
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
JP5863058B2 (ja) 2010-05-17 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １Ｈ−イミダゾ［４，５−ｃ］キノリン
DE102010025786A1 (de) * 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
CA2808624C (en) 2010-08-17 2019-05-14 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
EP2645999A2 (de) * 2010-12-03 2013-10-09 Novartis AG Pharmazeutische zusammensetzungen
CA2819955A1 (en) * 2010-12-06 2012-06-14 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3366311B1 (de) 2011-06-03 2020-02-26 3M Innovative Properties Co. Hydrazino-1h-imidazochinolin-4-amine und daraus hergestellte konjugate
WO2013007768A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
US20140309257A1 (en) * 2011-11-11 2014-10-16 The Regents Of The University Of Colorado, A Body Corporate Topoisomerase inhibitors and methods of making and use as therapeutic agents
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
HK1211476A1 (en) * 2012-08-16 2016-05-27 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
WO2014177915A1 (en) 2013-05-01 2014-11-06 Piramal Enterprises Limited Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US20160264570A1 (en) * 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
BR112016021383A2 (pt) 2014-03-24 2017-10-03 Genentech Inc Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
NO2714752T3 (de) * 2014-05-08 2018-04-21
JP6380777B2 (ja) * 2014-07-14 2018-08-29 アドヴェンチェン ファーマスーティカルズ，ナンジン リミテッド ＰＩ３Ｋ、ｍＴＯＲ阻害薬としての縮合キノリン化合物
DE102014226656A1 (de) 2014-12-19 2016-06-23 Robert Bosch Gmbh Verfahren zum Betreiben eines Abgasnachbehandlungssystems für eine Brennkraftmaschine
FR3031105B1 (fr) * 2014-12-31 2018-04-06 Universite De Montpellier Nouveaux imidazo[1,2-a]quinoxalines et derives pour le traitement des cancers
DK3277681T3 (da) 2015-04-02 2019-07-29 Merck Patent Gmbh Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
CN110078730B (zh) 2015-07-11 2021-09-07 南京爱德程医药科技有限公司 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN106496036A (zh) * 2016-09-29 2017-03-15 福建天富生物科技发展有限公司 一种抗凝血药物中间体5‑甲氧基‑2‑硝基苯甲酸的制备方法
CN110023312A (zh) 2016-10-13 2019-07-16 由卫生与公众服务部部长代表的美利坚合众国 阻止疟疾寄生虫传播的化合物和方法
CA3086439A1 (en) 2017-12-20 2019-06-27 3M Innovative Properties Company Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
KR102803409B1 (ko) 2019-06-06 2025-05-07 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Atr 키나제 억제제로서의 2,4,6-삼치환된 피리미딘 화합물
CN110606850A (zh) * 2019-09-11 2019-12-24 中山大学 一种3-苯并[4,5]咪唑[1,2-a]吡嗪-1-胺类化合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
GB8717644D0 (en) 1987-07-24 1987-09-03 Smithkline Beckman Intercredit Compounds
EP0385630B1 (de) * 1989-02-27 1996-11-27 Riker Laboratories, Inc. 4-Amino-1H-Imidazo(4,5-c)chinoline als antivirale Mittel
CA2011504C (en) 1989-03-07 1998-06-02 Kenji Ohmori Imidazoquinolone derivatives
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
GB8928281D0 (en) * 1989-12-14 1990-02-21 Smith Kline French Lab Compounds
EP0582581B1 (de) 1991-03-01 1999-05-06 Minnesota Mining And Manufacturing Company 1,2-substituierte 1h-imidazo[4,5-c]chinolin-4-amine
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH05213754A (ja) * 1992-02-03 1993-08-24 Kyowa Hakko Kogyo Co Ltd 抗潰瘍剤
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
WO1998030562A1 (en) * 1997-01-09 1998-07-16 Terumo Kabushiki Kaisha Novel amide derivatives and intermediates for the synthesis thereof
KR100251522B1 (ko) 1997-08-13 2000-08-01 김충섭 할로알콕시기를 함유하는 피롤[3,2-c]퀴놀린 유도체 및 약학적으로 허용되는 그의 염
JPH1180156A (ja) * 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
WO2001046190A1 (en) 1999-12-22 2001-06-28 Kyorin Pharmaceutical Co., Ltd. Tricyclic compounds and addition salts thereof
BR0108303A (pt) * 2000-02-09 2003-03-05 Hokuriku Pharmaceutical Derivados do 1h-imidazopiridina
WO2001097795A2 (en) 2000-06-22 2001-12-27 3M Innovative Properties Company Systems and methods for treating a mucosal surface
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US20040014779A1 (en) * 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways

Also Published As

Publication number Publication date
HK1074837A1 (en) 2005-11-25
CN1655788A (zh) 2005-08-17
BR0311221A (pt) 2005-03-01
EP1509521A2 (de) 2005-03-02
EP1509521B8 (de) 2009-02-18
US7998972B2 (en) 2011-08-16
CN100475207C (zh) 2009-04-08
DK1509521T3 (da) 2008-12-15
US20050245562A1 (en) 2005-11-03
AU2003240680A1 (en) 2003-12-02
CA2485012A1 (en) 2003-11-27
WO2003097641A3 (en) 2004-05-06
DE60323090D1 (de) 2008-10-02
GB0211649D0 (en) 2002-07-03
WO2003097641A2 (en) 2003-11-27
EP1509521B1 (de) 2008-08-20
ES2312783T3 (es) 2009-03-01
JP4707389B2 (ja) 2011-06-22
JP2005534636A (ja) 2005-11-17
SI1509521T1 (sl) 2009-02-28
AU2003240680A8 (en) 2003-12-02
PT1509521E (pt) 2008-11-25

Similar Documents

Publication Publication Date Title
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
BRPI0416796A (pt) compostos orgánicos
ATE400573T1 (de) 1h-imidazochinolinderivate als proteinkinaseinhibitoren
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
EA201101704A1 (ru) ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
TNSN06226A1 (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
WO2005097135A3 (en) Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
DE60135904D1 (de) Arzneien zur behandlung von nervenerkrankungen
DK1343472T3 (da) Thixotropisk næsespray
WO2004016741A3 (en) Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
ITMI20021866A1 (it) Preparazione farmaceutica in forma colloidale utile nella cura delle affezioni cutanee.
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
ATE338560T1 (de) Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung
ATE224730T1 (de) Mittel zur behandlung von pigmentierungsstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1509521

Country of ref document: EP